Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Guillaume Beziat; Martin Gauthier; Caroline Protin; Lucie Oberic; Fleur Lerebours; Jasmine Carlier; Loïc Ysebaert

doi:10.1002/ccr3.2580

Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report

Clin Case Rep. 2020 Jan 10;8(2):269-273. doi: 10.1002/ccr3.2580. eCollection 2020 Feb.

Authors

Guillaume Beziat¹, Martin Gauthier¹, Caroline Protin¹, Lucie Oberic¹, Fleur Lerebours², Jasmine Carlier², Loïc Ysebaert¹

Affiliations

¹ Department of Hematology Institut Universitaire du Cancer de Toulouse-Oncopole Toulouse France.
² Department of Neurology CHU Purpan Toulouse France.

Abstract

Venetoclax with high-dose methotrexate and rituximab seem effective and safe to treat central nervous system involvement of chronic lymphocytic leukemia.

Keywords: central nervous system involvement; chronic lymphocytic leukemia; venetoclax.

Publication types

Case Reports